Market Overview:
The global biosimilars treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of chronic and autoimmune diseases, rising demand for cost-effective therapies, and growing awareness about biosimilars. The biosimilars treatment market is segmented on the basis of type into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing demand for these therapies due to their high efficacy and safety profile. Oncology is currently one of the largest application segments for biosimilars treatments globally. This trend is expected to continue during the forecast period owing to rising incidence rates of cancer across all regions worldwide.
Product Definition:
Biosimilars are treatments that are very similar to already approved biologic drugs, but they are not exactly the same. Biosimilars must meet strict quality standards, and they must be proven to be safe and effective in clinical trials before they can be approved by the FDA.
Biosimilars offer an important new treatment option for patients with serious illnesses such as cancer, rheumatoid arthritis, and Crohn's disease. Biosimilar drugs can help reduce health care costs by providing an affordable alternative to expensive biologic drugs.
Recombinant Non – Glycosylated Proteins:
Recombinant non - glycosylated proteins are a group of highly diverse products, which can be used as growth factors in the biosimilar treatment market. The recombinant proteins have several advantages over conventional ones, such as they are more stable and do not cause any immune response.
Recombinant Glycosylated Proteins:
Recombinant glycosylated proteins are a group of highly diverse molecules, which can be used as immunogenics or vaccine carriers. They comprise an N-linked oligosaccharide chain and usually three to four different polypeptide chains. The recombinant glycosylated protein is linked to an antibody by way of an N-linked oligosaccharide linker which allows the immune system recognition without compromising the biological activity of the molecule.
Application Insights:
On the basis of application, the global biosimilars treatment market is segmented into oncology, infectious diseases, chronic and autoimmune disease, blood disorders and growth hormone disease. The infectious diseases segment held a significant share in 2017 owing to increasing prevalence of HIV infection and rising demand for effective antiretroviral therapy.
The chronic and autoimmune disease segment is expected to witness lucrative growth over the forecast period due to high unmet medical needs in this sector along with growing incidence of type 1 & 2 diabetes mellitus across the globe. Furthermore, an increase in cancer cases has resulted in increased usage of biosimilars as a substitute for conventional therapies such as chemotherapy which will boost its demand further during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and rising investment by companies in R&D are some of the factors responsible for its continued dominance over the forecast period. In addition, increasing biosimilar penetration and growing demand for treatment options other than biologics are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the coming years owing to a rise in approvals from regulatory agencies such as China FDA and Japan FDA coupled with an increase in product launch by manufacturers operating within this region. Furthermore, economic development within countries such as India has led to improvement in healthcare infrastructure which is further expected to boost regional market growth during 2018-2030 time span.
Growth Factors:
- Increasing incidence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases (NCDs) such as cancer, cardiovascular disease, diabetes, and respiratory disorders account for 63% of all deaths worldwide. This number is expected to rise to 73% by 2030. This presents a huge opportunity for biosimilars manufacturers as these drugs are used to treat chronic conditions.
- Rising healthcare expenditure: Healthcare spending is on the rise globally due to factors such as aging populations, rising income levels, and technological advancements in the medical field. In 2017, global healthcare spending was estimated at trillion and it is projected to grow at a CAGR of 6% between 2018 and 2022., This provides a huge opportunity for biosimilars manufacturers as they can tap into this growing market segment..
Scope Of The Report
Report Attributes
Report Details
Report Title
Biosimilars Treatment Market Research Report
By Type
Recombinant Non – Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides
By Application
Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Hormone Disease, Infectious Disease
By Companies
Bayer, Eli Lily, Inc., Pfizer, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Amgen Inc., Biocon, Dr. Reddy’s Laboratories, Roche Ltd., Celltrion, Inc., Samsung Bioepis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
153
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Biosimilars Treatment Market Report Segments:
The global Biosimilars Treatment market is segmented on the basis of:
Types
Recombinant Non – Glycosylated Proteins, Recombinant Glycosylated Proteins, Recombinant Peptides
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Chronic and Autoimmune Disease, Blood Disorders, Growth Hormone Disease, Infectious Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Eli Lily, Inc.
- Pfizer, Inc.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Limited
- Amgen Inc.
- Biocon
- Dr. Reddy’s Laboratories
- Roche Ltd.
- Celltrion, Inc.
- Samsung Bioepis
Highlights of The Biosimilars Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant Non – Glycosylated Proteins
- Recombinant Glycosylated Proteins
- Recombinant Peptides
- By Application:
- Oncology
- Chronic and Autoimmune Disease
- Blood Disorders
- Growth Hormone Disease
- Infectious Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biosimilars Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biosimilars are a type of medication that are similar to the original brand name medications, but they have been modified in order to make them more affordable and easier to produce.
Some of the major players in the biosimilars treatment market are Bayer, Eli Lily, Inc., Pfizer, Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Amgen Inc., Biocon, Dr. Reddy’s Laboratories, Roche Ltd., Celltrion, Inc., Samsung Bioepis.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Biosimilars Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Biosimilars Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Biosimilars Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Biosimilars Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Biosimilars Treatment Market Size & Forecast, 2020-2028
4.5.1 Biosimilars Treatment Market Size and Y-o-Y Growth
4.5.2 Biosimilars Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Recombinant Non – Glycosylated Proteins
5.2.2 Recombinant Glycosylated Proteins
5.2.3 Recombinant Peptides
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Chronic and Autoimmune Disease
6.2.3 Blood Disorders
6.2.4 Growth Hormone Disease
6.2.5 Infectious Disease
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Biosimilars Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Biosimilars Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Recombinant Non – Glycosylated Proteins
9.6.2 Recombinant Glycosylated Proteins
9.6.3 Recombinant Peptides
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Chronic and Autoimmune Disease
9.10.3 Blood Disorders
9.10.4 Growth Hormone Disease
9.10.5 Infectious Disease
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Recombinant Non – Glycosylated Proteins
10.6.2 Recombinant Glycosylated Proteins
10.6.3 Recombinant Peptides
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Chronic and Autoimmune Disease
10.10.3 Blood Disorders
10.10.4 Growth Hormone Disease
10.10.5 Infectious Disease
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Recombinant Non – Glycosylated Proteins
11.6.2 Recombinant Glycosylated Proteins
11.6.3 Recombinant Peptides
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Chronic and Autoimmune Disease
11.10.3 Blood Disorders
11.10.4 Growth Hormone Disease
11.10.5 Infectious Disease
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Recombinant Non – Glycosylated Proteins
12.6.2 Recombinant Glycosylated Proteins
12.6.3 Recombinant Peptides
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Chronic and Autoimmune Disease
12.10.3 Blood Disorders
12.10.4 Growth Hormone Disease
12.10.5 Infectious Disease
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Recombinant Non – Glycosylated Proteins
13.6.2 Recombinant Glycosylated Proteins
13.6.3 Recombinant Peptides
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Chronic and Autoimmune Disease
13.10.3 Blood Disorders
13.10.4 Growth Hormone Disease
13.10.5 Infectious Disease
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Biosimilars Treatment Market: Competitive Dashboard
14.2 Global Biosimilars Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Eli Lily, Inc.
14.3.3 Pfizer, Inc.
14.3.4 Sandoz International GmbH
14.3.5 Teva Pharmaceutical Industries Limited
14.3.6 Amgen Inc.
14.3.7 Biocon
14.3.8 Dr. Reddy’s Laboratories
14.3.9 Roche Ltd.
14.3.10 Celltrion, Inc.
14.3.11 Samsung Bioepis
